Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth with 0.5mg oral finasteride daily, despite a minoxidil allergy, and reported no side effects. They also used a keto shampoo and were satisfied with the results.

The user resumed taking 5mg oral minoxidil and 0.5mg dutasteride daily, with vitamins, and noticed hair regrowth. They switched from finasteride to dutasteride due to side effects and prefer oral minoxidil over topical for convenience and effectiveness.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The conversation discusses purchasing Avodart (dutasteride) at a low price, with the OP using 1mg daily for hair loss. Users inquire about the source, and OP confirms buying from Oxford Pharmacy in the UK.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

Transitioning from finasteride to dutasteride for hair loss, with suggestions to either slowly transition or frontload dutasteride. The user is also using minoxidil, nizoral, needling, and LLLT.

The user stopped oral minoxidil due to side effects and is now using dutasteride mesotherapy and plans to start oral dutasteride. They are concerned about potential hair shedding and wonder if dutasteride alone will be effective.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

A 24-year-old is experiencing hair shedding and regrowth while using dutasteride (1mg), vitamin D, and minoxidil (5%). Others share similar experiences with hair loss treatments like minoxidil and finasteride.

The user continues to experience hair loss despite using dutasteride 2.5mg, minoxidil 5mg, and ciclopirox shampoo, and plans to reassess after one year. Others report similar issues with dutasteride, with some switching to finasteride or adding RU58841.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

User wants to mix finasteride into stemoxydine instead of minoxidil. Seeks stemoxydine brand recommendations for mixing in the UK.

Higher doses of dutasteride reduce scalp DHT more effectively than finasteride, but have diminishing returns after 3mg daily and may cause more side effects. Combining dutasteride with topical minoxidil can enhance results, but using both finasteride and dutasteride together is unnecessary.

A user's 11-month hair loss treatment progress using 0.5mg dutasteride every other day, 50mg RU58841 in the morning, 5mg oral minoxidil, topical minoxidil at night, and microneedling with a 1.5mm needle every other week. The user's improvement was significant, going from a severe hair loss stage (NW7) to a mild/moderate stage (NW2-3).

The user experienced significant hair regrowth using finasteride and minoxidil. They plan to switch to dutasteride for its potency after confirming their body's tolerance to DHT blockers.

A user shared their 5-month hair regrowth progress using 0.5mg Dutasteride daily and 5% Minoxidil foam twice daily, reporting significant improvement despite initial shedding. Other users discussed their experiences with similar treatments, noting varied results and side effects, with some emphasizing the need for long-term commitment to maintain hair growth.

A user shared their experience using dutasteride for hair loss, noting subtle improvements and thicker hair without significant regrowth. They did not use finasteride or minoxidil, and experienced occasional shedding but no side effects.

Dutasteride is generally considered more effective than finasteride for hair regrowth, with some users experiencing better results, especially at higher doses. However, individual responses vary, and some users report side effects or no response to either treatment.

The conversation is about someone being prescribed Dutasteride for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.

The user is experiencing positive results in hair regrowth using a regimen of 0.5 mg dutasteride, 5 mg oral minoxidil, ketoconazole shampoo, microneedling, and a combination of topical minoxidil with RU58841. They report no side effects and express gratitude for the support and inspiration from the community.